title: Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.
authors.forename: D
authors.initials: D
authors.lastname: Rea
authors.forename: G
authors.initials: G
authors.lastname: Etienne
authors.forename: S
authors.initials: S
authors.lastname: Corm
authors.forename: P
authors.initials: P
authors.lastname: Cony-Makhoul
authors.forename: M
authors.initials: M
authors.lastname: Gardembas
authors.forename: L
authors.initials: L
authors.lastname: Legros
authors.forename: V
authors.initials: V
authors.lastname: Dubruille
authors.forename: S
authors.initials: S
authors.lastname: Hayette
authors.forename: F-X
authors.initials: FX
authors.lastname: Mahon
authors.forename: J-M
authors.initials: JM
authors.lastname: Cayuela
authors.forename: F E
authors.initials: FE
authors.lastname: Nicolini
mesh_terms: D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D020714:Maximum Tolerated Dose; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate